Literature DB >> 25036881

Tear exchangeable limbal rigid contact lens for ocular sequelae resulting from Stevens-Johnson syndrome or toxic epidermal necrolysis.

Chie Sotozono1, Naoki Yamauchi2, Soshun Maeda2, Shigeru Kinoshita3.   

Abstract

PURPOSE: To evaluate the therapeutic benefits of tear-exchangeable, limbal, rigid contact lenses (limbal CLs) in patients with Stevens-Johnson syndrome- or toxic epidermal necrolysis-associated ocular sequelae.
DESIGN: Noncomparative, retrospective, interventional case series.
METHODS: We enrolled 53 eyes of 42 patients (mean age, 51.8 ± 13.9 years; mean follow-up, 25.7 ± 15.7 months) with Stevens-Johnson syndrome- or toxic epidermal necrolysis-associated ocular sequelae and divided them into 3 groups according to the best-corrected visual acuity (BCVA) before limbal CL fitting: (1) BCVA worse than 20/2000 (11 eyes), (2) BCVA ranging from 20/200 to 20/2000 (31 eyes), and (3) BCVA of 20/200 or better (11 eyes). The BCVA and the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score before fitting and after 3 months of limbal CL use were evaluated. The change in BCVA (in logarithm of the minimal angle of resolution [logMAR] units) and 25-item National Eye Institute Visual Function Questionnaire composite score change were compared among the 3 groups.
RESULTS: Best-corrected visual acuity improved from 1.61 to 0.86 logMAR at 3 months after fitting CL use. Improvement in BCVA in groups 1, 2, and 3 was 0.95 logMAR, 0.82 logMAR, and 0.37 logMAR, respectively. The mean 25-item National Eye Institute Visual Function Questionnaire composite score for the 11 subscales improved from 37.6 ± 16.0 to 58.4 ± 17.4 (P = .000001). All 11 subscores, except that for driving ability, improved significantly. The general vision subscore improved most in group 3, yet the general health subscore improved most in group 1. No serious adverse events attributable to limbal CL use occurred.
CONCLUSIONS: The tear-exchangeable limbal CL is safe and effective for the improvement of vision and quality of life in Stevens-Johnson syndrome or toxic epidermal necrolysis patients with severe ocular sequelae.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25036881     DOI: 10.1016/j.ajo.2014.07.012

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

Review 1.  Limbal-Rigid Contact Lens Wear for the Treatment of Ocular Surface Disorders: A Review.

Authors:  Yulia Aziza; Motohiro Itoi; Mayumi Ueta; Tsutomu Inatomi; Shigeru Kinoshita; Chie Sotozono
Journal:  Eye Contact Lens       Date:  2022-07-08       Impact factor: 3.152

2.  Prosthetic Replacement of the Ocular Surface Ecosystem Treatment for Ocular Surface Disease in Pediatric Patients With Stevens-Johnson Syndrome.

Authors:  Yvonne Wang; Rohini Rao; Deborah S Jacobs; Hajirah N Saeed
Journal:  Am J Ophthalmol       Date:  2019-01-19       Impact factor: 5.258

3.  Clinical outcomes and complications of fluid-filled scleral lens devices for the management of limbal stem cell deficiency.

Authors:  Clémence Bonnet; Andrew Lee; Vivian P Shibayama; Chi-Hong Tseng; Sophie X Deng
Journal:  Cont Lens Anterior Eye       Date:  2021-10-30       Impact factor: 3.946

Review 4.  Recovering vision in corneal epithelial stem cell deficient eyes.

Authors:  Kiranjit K Bains; Hideki Fukuoka; Greg M Hammond; Chie Sotozono; Andrew J Quantock
Journal:  Cont Lens Anterior Eye       Date:  2019-04-29       Impact factor: 3.077

5.  Editorial: The Updated Understanding of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Shigeru Kinoshita; Mayumi Ueta
Journal:  Front Med (Lausanne)       Date:  2021-12-22

6.  Challenges in the management of bilateral eyelid closure in Stevens-Johnson Syndrome.

Authors:  Yulia Aziza; Kohei Harada; Mayumi Ueta; Hideki Fukuoka; Shigeru Kinoshita; Chie Sotozono
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-05

7.  Regression of corneal opacity and neovascularization in Stevens-Johnson syndrome and Toxic Epidermal Necrolysis with the use of prosthetic replacement of the ocular surface ecosystem (PROSE) treatment.

Authors:  Jennifer Liao; Bita Asghari; Karen G Carrasquillo
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-14

Review 8.  Acute and Chronic Management of Ocular Disease in Stevens Johnson Syndrome/Toxic Epidermal Necrolysis in the USA.

Authors:  Derek Metcalfe; Omer Iqbal; James Chodosh; Charles S Bouchard; Hajirah N Saeed
Journal:  Front Med (Lausanne)       Date:  2021-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.